mIHC staining revealed that, compared to BTC patient samples with no response to camrelizumab combined with apatinib treatment, tumour tissues from responders exhibited significantly higher levels of CD4+ and CD8+ T cell infiltration (Figure S4D). Here, CD8A is linked to neoplasm.